Results 161 to 170 of about 20,247 (196)

Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma

Clinical and Translational Oncology, 2019
CD47 over expression has been reported in several tumor subtypes. CD47 interacts with SIRPalpha on macrophages inhibiting phagocytic signal, providing a survival advantage to tumor. CD47, therefore, represents a valuable target for immunotherapy and is currently under clinical investigation.
B. López-Pereira, A. A. Fernández-Velasco, I. Fernández-Vega, D. Corte-Torres, C. Quirós, J. A. Villegas, P. Palomo, S. González, A. P. González, Á. Payer, T. Bernal, M. A. Moro-García, R. Alonso-Arias, S. Alonso-Álvarez, E. Colado   +14 more
openaire   +2 more sources

Abstract 2944: Trastuzumab-deruxtecan (T-Dxd) induces superior macrophage/DC activation, antigen-presentation and anti-tumor adaptive immune responses, which can be augmented by CD47/SIRPA blockade

Cancer Research, 2023
Abstract Background: T-DXd is a new antibody-drug conjugate targeting HER2 that has demonstrated superior clinical efficacy over previous HER2-targeting agent Trastuzumab emtansine (T-DM1) in patients with advanced-stage HER2+ breast cancer (BC).
Li-Chung Tsao, Zachary Conrad Hartman
openaire   +1 more source

Influence of polymer architecture on antigens camouflage, CD47 protection and complement mediated lysis of surface grafted red blood cells

Biomaterials, 2012
Hyperbranched polyglycerol (HPG) and polyethylene glycol (PEG) polymers with similar hydrodynamic sizes in solution were grafted to red blood cells (RBCs) to investigate the impact of polymer architecture on the cell structure and function. The hydrodynamic sizes of polymers were calculated from the diffusion coefficients measured by pulsed field ...
Rafi, Chapanian, Iren, Constantinescu, Nicholas A A, Rossi, Nadia, Medvedev, Donald E, Brooks, Mark D, Scott, Jayachandran N, Kizhakkedathu   +6 more
openaire   +2 more sources

Anti‐ CD47 drug interference in pre‐transfusion testing can be overcome by antigen masking

Transfusion
Abstract Background Overexpression of CD47, a “don't eat me” signal for macrophages, in various malignancies has prompted the development of anti‐CD47 therapies. Although the first‐in‐class anti‐CD47 antibody magrolimab was abandoned due to its ineffectiveness in improving survival in acute ...
Cora P. Habicht, Svenja Adolph, Daniela Grüger, Rafaela Hervatin, Stephan Immenschuh, Jana Králová, Clemens Schneeweiß   +6 more
openaire   +2 more sources

CD47 Deficiency Ameliorates Ocular Autoimmune Inflammation

Frontiers in Immunology, 2021
Yoko Okunuki, Kip Connor, Connor Kip M
exaly  

Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent

Arteriosclerosis, Thrombosis, and Vascular Biology, 2021
Charlotte Kawecki, Thomas Sarazin, C E H Schmelzer   +2 more
exaly  

The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions

Cancer Cell, 2023
Juan C Osório, David Knorr, Jeffrey Ravetch   +2 more
exaly  

ANTIGEN-BINDING POLYPEPTIDE BINDING TO CD47, AND USE THEREOF

2021
GUI QIU, ZHU HONG, WANG LIANGLIANG, ZHANG XIAOYUN, ZOU XIAOFANG, SHEN HENGQIAO, XU HONGJIANG, YANG LING   +7 more
openaire   +3 more sources

Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis

Journal of Cell Biology, 2023
, Triantafyllos Chavakis, Karim El Kasmi   +2 more
exaly  

ANTI-CD47 ANTIGEN BINDING PROTEIN, AND APPLICATION THEREOF

2021
GROSVELD FRANK, DRABEK DUBRAVKA, VAN HAPEREN MARINUS (RIEN), JANSSENS RICK, WANG LUFAN, LIU BIN, RONG YIPING, HE YUN, ZHOU WEI   +8 more
openaire   +1 more source